Search results
Results from the WOW.Com Content Network
Desmoplastic reaction to breast cancer. Desmoplasia refers to growth of dense connective tissue or stroma. [2] This growth is characterized by low cellularity with hyalinized or sclerotic stroma and disorganized blood vessel infiltration. [3] This growth is called a desmoplastic response and occurs as result of injury or neoplasia. [2]
Sclerotic fibromas [1] are a cutaneous condition characterized by well-circumscribed, dome-shaped, dermal hypocellular nodules composed predominantly of sclerotic thick collagen bundles. [ 2 ] See also
Systemic scleroderma, or systemic sclerosis, is an autoimmune rheumatic disease characterised by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs and by injuries to small arteries. There are two major subgroups of systemic sclerosis based on the extent of skin involvement: limited and diffuse ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Atherosclerosis [a] is a pattern of the disease arteriosclerosis, [8] characterized by development of abnormalities called lesions in walls of arteries.This is a chronic inflammatory disease involving many different cell types and driven by elevated levels of cholesterol in the blood. [9]
The mTOR inhibitor everolimus was approved in the US for treatment of TSC-related tumors in the brain (subependymal giant cell astrocytoma) in 2010 and in the kidneys (renal angiomyolipoma) in 2012. [ 26 ] [ 27 ] Oral everolimus (rapalog) reduces tumour size, is effective in terms of response to skin lesions and does not increase the risk of ...
An advantage is the cosmetic result: after treatment, the skin resembles normal skin without the usual scarring and morbidity associated with standard excision. Imiquimod is not FDA-approved for any squamous-cell carcinoma. In general, squamous-cell carcinomas have a high risk of local recurrence, and up to 50% do recur. [60]
Nausea and vomiting are two of the most feared cancer treatment-related side-effects for people with cancer and their families. In 1983, Coates et al. found that people receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. [ 98 ]